Express Scripts expects earnings increase next year; India may exempt Sanofi's dengue vax from trials;

@FiercePharma: Shift in law helps local pharma groups in the Philippines. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: WuXi clarifies just what AstraZeneca is buying, or actually what it isn't buying. Report | Follow @EricPFierce

@CarlyHFierce: Valeant's rep-retention plan worked. Now, its sales folks are 'ready and waiting.' FiercePharmaMarketing story | Follow @CarlyHFierce

> Leading PBM Express Scripts ($ESRX) expects 2016 adjusted earnings of $6.08-$6.28 per share, an increase of 10% to 14% from the company's reaffirmed guidance for 2015. Report

> India's government may exempt Sanofi's ($SNY) dengue vaccine, Dengvaxia, from large-scale clinical trials. Report

> Genmab has achieved a $3 million milestone payment in its DuoBody collaboration with Johnson & Johnson's ($JNJ) Janssen. More

> Sobi has received an orphan drug designation for hemophilia med Alprolix in Switzerland. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: UCLA spinout nabs $10M Series A to diagnose, track traumatic brain injury. Report | Follow @FierceMedDev

@EmilyWFierce: Hey doc, what's on the menu when pharma comes calling? Hint: It's not health food. Story from FiercePharmaMarketing | Follow @EmilyWFierce

> Micro-cap liquid biopsy Dx player Biocept nabs $15M financing from Chicago growth investor. Report

> Olympus played down early report of superbug infections linked to duodenoscope devices. Article

Biotech News

@FierceBiotech: As trouble mounts, a chastened Martin Shkreli says bad boy persona was just an 'experiment.' Article | Follow @FierceBiotech

@JohnCFierce: Orbimed rings up $950M for biotech Fund VI. Report | Follow @JohnCFierce

@DamianFierce: this is a particularly belabored headline. FDA release | Follow @DamianFierce

> Pfizer, Merck KGaA launch two more PhIII trials for avelumab. Item

> Baxalta and Momenta target AbbVie's blockbuster with positive biosim data. Article

> With Big Pharma backing, eFFECTOR plots solid tumor trial with $40M round. Report

> pSivida shares soar as eye drug/device passes its first PhIII test. Story

Pharma Manufacturing News

> Sun said to be discussing $2.3B deal for Intas: DealStreetAsia. Item

> GSK recalls nearly 130,000 Ventolin inhalers. More

> Alnylam looks at building $100M plant outside Cambridge. Story

> Novartis selling French Alcon plant to Recipharm. Article

> Sun says the FDA has issued warning letter for Halol plant. Report

Drug Delivery News

> Antibiotic gel can prevent infection in bone implants. Report

> Eli Lilly partners with Halozyme to develop subcutaneous injectables. News

> FDA approves first chewable extended-release tablet, creating new drug delivery partnership opportunity. More

> J&J's Janssen teams up with Intrexon for diabetes pill. Story

> Startup gets $7M in funding to test its toenail fungus-fighting micro-insert. Article

Pharma Asia News

> Shift in law helps local pharma groups in the Philippines. Item

> Sun Pharma said to be in talks to buy Intas for $2.3B. Story

> 2015 was the year of the (most likely Chinese) health hacker: FT. More

> SciClone Pharmaceuticals sets mucositis treatment for China. Item

> Indian M&A deals top $1.5B in 2015 led by overseas acquisitions. Article

And Finally... The pharma industry will give £200 million to the U.K.'s NHS in early rebate payments to help it pay for meds. More

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.